LINKIN PARK TO ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI
Pepsi reveals the iconic global superstars will headline the UCL final's unmissable annual…
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiologys Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and…
Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36…
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery…
Gulf Beverages presented and honored Dubai Duty Free with the Exclusive Rampur Signature Reserve, in the presence of Radico Khaitan Team
NEW DELHI, Feb. 28, 2025 /PRNewswire/ -- Gulf Beverages proudly presented Dubai…
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
February 23, 2025 12:07 ET | Source: IO Biotech • Findings support…
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior…